Clinical evaluation patients
110 patients
- EndpointRetrospective CleaRecon DL image-quality evaluation
- Population3DXR
- Tested version3DXR release with CleaRecon DL
FDA-cleared profile
GE Medical Systems SCS · Fluoroscopy/Angiography · FDA-cleared (510(k))
Authorized purpose: 3DXR reconstructs cone-beam CT from interventional X-ray acquisitions and uses CleaRecon DL to reduce streak artifacts for display in the advanced workstation workflow.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: 3DXR reconstructs cone-beam CT from interventional X-ray acquisitions and uses CleaRecon DL to reduce streak artifacts for display in the advanced workstation workflow.
Evidence takeaway. Evidence from the reviewed source record: K243446 reports a retrospective clinical image-quality study of 110 patients from 13 sites reviewed by 13 clinicians, plus nonclinical reconstruction validation.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The exact input is 3D-acquisition images from the X-ray interventional system, not the dossier's multi-modality image set and user-input wording.
The packet identifies the reconstructed 3D volume and Volume Viewer output, not the dossier's generic landmarks, measurements, overlays, or navigation guidance.
The indications statement says the reconstructed volume assists the physician and does not establish technologists or procedural staff as intended users.
The packet's comparison table gives the adult-population validation boundary for CleaRecon DL.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
110 patients
13 readers
K243446
Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Exact-identifier review does not prove absence of all product-family safety signals.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesBuild a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Any images acquired with a 3D Acquisition mode of the X-ray interventional system.
Scope: Exact FDA submission. The exact input is 3D-acquisition images from the X-ray interventional system, not the dossier's multi-modality image set and user-input wording.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-19 · FDA K243446: 3DXR
Source context, not route validation: Validate compatible imaging hardware, acquisition geometry, displays, workstation, exported objects, latency, calibration, and fallback workflow.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-03 · FDA K243446: 3DXR
Source context, not route validation: Procedure-room hardware and software or a connected workstation with supported imaging equipment and accessories.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-03 · FDA K243446: 3DXR
Source context, not route validation: The reconstructed 3D volume is visualized under Volume Viewer.
Scope: Exact FDA submission. The packet identifies the reconstructed 3D volume and Volume Viewer output, not the dossier's generic landmarks, measurements, overlays, or navigation guidance.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-19 · FDA K243446: 3DXR
Unresolved route: The reconstructed 3D volume is visualized under Volume Viewer.
Scope: Exact FDA submission. The packet identifies the reconstructed 3D volume and Volume Viewer output, not the dossier's generic landmarks, measurements, overlays, or navigation guidance.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-19 · FDA K243446: 3DXR
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Map the installed model, build, options, population, anatomy, inputs, and outputs to K243446 before acceptance.
exact submission · checked 2026-09-03Later product-family features are not evidence that this cleared release includes them.
Validate compatible imaging hardware, acquisition geometry, displays, workstation, exported objects, latency, calibration, and fallback workflow.
exact submission · checked 2026-09-03Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The operator remains responsible for procedural decisions, source-image review, landmark confirmation, and fallback when inputs, tracking, calibration, or output quality are inadequate.
exact submission · checked 2026-09-03Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: The operator remains responsible for procedural decisions, source-image review, landmark confirmation, and fallback when inputs, tracking, calibration, or output quality are inadequate.
exact submission · checked 2026-09-03Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The packet's classification name is an image-intensified fluoroscopic x-ray system; it does not use the dossier's Fluoroscopy/Angiography label. Controlled directory display reconciled from exact FDA wording: Image-intensified fluoroscopic x-ray system. -> Fluoroscopy/Angiography.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
6 sources - 3 history items
Scope: purpose, anatomy, evidenceSummary, modality, intendedUsers, input, output, limitations, clinicalUse
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Therenva SAS
Authorized purpose: EndoNaut fuses planning images with live fluoroscopy and provides computerized navigation support for fluoroscopy-guided aneurysm repair, embolization, and peripheral-artery procedures involving the chest, abdomen, pelvis, neck, or lower limbs.
Siemens Medical Solutions
Authorized purpose: LUMINOS Q.namix T and LUMINOS Q.namix R are multifunctional radiography and fluoroscopy systems for routine radiography and fluoroscopic examinations including gastrointestinal, urogenital, arthrographic, angiographic, and pediatric workflows; they are not mammography systems.
Therenva SAS
EndoNaut overlays preoperative three-dimensional vascular anatomy on live fluoroscopy and supports semi-automatic registration and motion detection for selected aneurysm, angioplasty, stenting, and embolization procedures.
Omega Medical Imaging, LLC
Authorized purpose: CS-series-FP radiographic and fluoroscopic systems support cardiac, vascular, general, and interventional procedures; FluoroShield provides secondary region-of-interest collimation with lower-refresh peripheral context.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history